Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.530
-0.170 (-4.59%)
At close: Aug 1, 2025, 4:00 PM
3.670
+0.140 (3.97%)
After-hours: Aug 1, 2025, 6:46 PM EDT

Company Description

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors.

It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.

In addition, the company develops MP0621, a molecular partners’ first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.

It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates.

Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG
Molecular Partners AG logo
CountrySwitzerland
Founded2004
IPO DateJun 16, 2021
IndustryBiotechnology
SectorHealthcare
Employees159
CEOPatrick Amstutz

Contact Details

Address:
Wagistrasse 14
Schlieren, 8952
Switzerland
Phone41 44 755 77 00
Websitemolecularpartners.com

Stock Details

Ticker SymbolMOLN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyCHF
IPO Price$21.25
CIK Code0001745114
CUSIP Number60853G106
ISIN NumberUS60853G1067
SIC Code2836

Key Executives

NamePosition
Dr. Patrick Amstutz Ph.D.Co-Founder, Chief Executive Officer, Member of Management Board and Director
Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive Vice President of Projects and Member of Management Board
Robert HendriksSenior Vice President of Finance
Alexander ZurcherChief Operating Officer and Member of Management Board
Renate GloggnerExecutive Vice President of People and Community and Member of Management Board
Dr. Philippe Legenne M.B.A., M.D.Chief Medical Officer and Member of the Management Board
Daniel Steiner Ph.D.Senior Vice President of Research and Technology
Seth D. LewisSenior Vice President of Investor Relations, Communications and Strategy
Michael PitznerGeneral Counsel, Compliance Officer, Senior Vice President Legal and Business Development
Dr. Pamela A. Trail Ph.D.Strategic Consultant

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jun 25, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 12, 20256-KReport of foreign issuer
May 15, 20256-KReport of foreign issuer
May 2, 2025SCHEDULE 13GFiling
Apr 29, 20256-KReport of foreign issuer
Apr 24, 2025EFFECTNotice of Effectiveness
Apr 21, 2025UPLOADFiling
Apr 11, 2025F-3Filing
Mar 6, 20256-KReport of foreign issuer